Enhancing medicine price transparency through price information mechanisms

Globalization and Health

Sarah Schmitt¹  Miloud Kaddar¹  Michael Hinsch¹ 

[1] Expanded Programme on Immunization (EPI), Department of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Avenue Appia 20, Geneva 1211, Switzerland

关键词: Access to medicines;    Procurement;    Price transparency;    Medicine price information mechanisms;   

Others  :  802363
DOI  :  10.1186/1744-8603-10-34

 received in 2013-07-31, accepted in 2014-03-19,  发布年份 2014

【 摘 要 】

Background

Medicine price information mechanisms provide an essential tool to countries that seek a better understanding of product availability, market prices and price compositions of individual medicines. To be effective and contribute to cost savings, these mechanisms need to consider prices in their particular contexts when comparing between countries. This article discusses in what ways medicine price information mechanisms can contribute to increased price transparency and how this may affect access to medicines for developing countries.

Methods

We used data collected during the course of a WHO project focusing on the development of a vaccine price and procurement information mechanism. The project collected information from six medicine price information mechanisms and interviewed data managers and technical experts on key aspects as well as observed market effects of these mechanisms.

The reviewed mechanisms were broken down into categories including objective and target audience, as well as the sources, types and volumes of data included. Information provided by the mechanisms was reviewed according to data available on medicine prices, product characteristics, and procurement modalities.

Results

We found indications of positive effects on access to medicines resulting from the utilization of the reviewed mechanisms. These include the uptake of higher quality medicines, more favorable results from contract negotiations, changes in national pricing policies, and the decrease of prices in certain segments for countries participating in or deriving data from the various mechanisms.

Conclusion

The reviewed mechanisms avoid the methodological challenges observed for medicine price comparisons that only use national price databases. They work with high quality data and display prices in the appropriate context of procurement modalities as well as the peculiarities of purchasing countries. Medicine price information mechanisms respond to the need for increased medicine price transparency and have the potential to contribute to improved access to medicines in developing countries.

Additional research is required to explore more specific aspects. These include the market effects of dedicated donor funds for certain medicines to explain the driving force of user demands, and the effects of increased price transparency on different groups of medicines in context of the maturity of their markets.

【 授权许可】

   
2014 Hinsch et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Kyle MK, Ridley DB: Would greater transparency and uniformity of health care prices benefit poor patients? Health Aff 2007, 26(5):1384-1391.
• [2]U.S. Food and Drug Administration: Generic drugs: questions and answers. http://www.fda.gov/drugs/resourcesforyou/consumers/questionsanswers/ucm100100.htm webcite. (Accessed 28 June, 2013)
• [3]World Health Organization: More Equitable Pricing for Essential Drugs: What do we Mean and What are the Issues? In Background Paper for the WHO-WTO Secretariat Workshop on Differential Pricing and Financing of Essential Drugs: 8–11 April 2001. Geneva, Switzerland: Høsbjør; 2001.
• [4]World Health Organization, Health Action International: Measuring Medicine Prices, Availability and Price Components. 2nd edition. Geneva, Switzerland: World Health Organization; 2008.
• [5]World Health Organization: World Health Statistics 2012. Geneva, Switzerland: World Health Organization; 2012.
• [6]World Health Organization: The World Medicines Situation 2011. Medicines Prices, Availability and Affordability. Geneva, Switzerland: World Health Organization; 2011.
• [7]Management Sciences for Health, World Health Organization: International Drug Price Indicator Guide. 2010 edition. Cambridge MA, USA: Management Sciences for Health; 2010.
• [8]Morgan S, Daw J, Thomson P: International best practices for negotiating ‘reimbursement contracts’ with price rebates from pharmaceutical companies. Health Affairs 2013, 32(4):771-777.
• [9]World Health Assembly: 54th World Health Assembly: WHO medicines strategy: 21 May 2001. Geneva; Switzerland: World Health Organization; 2001.
• [10]Austin AD, Gravelle J: Does Price Transparency Improve Market Efficiency? Implications of Empirical Evidence in Other Markets for the Health Sector. In CRS Report for Congress, RL34101, 24 July 2007. Washington, D.C.: U.S: Congressional Research Service; 2007.
• [11]Stigler GJ: The economics of information. J Pol Econ 1961, 69(3):213-225.
• [12]Pauly MV, Burns LR: Price transparency for medical devices. Health Affairs 2008, 27(6):1544-1553.
• [13]Hviid M, Møllgaard HP: Countervailing power and price transparency. Scand J Econ 2006, 108(3):499-512.
• [14]Ridley DB: Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics 2005, 23(7):651-658.
• [15]Outterson K: Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale J Health Policy Law Ethics 2005, 5(1):193-292.
• [16]Pauly MV: Commentary. Drug and vaccine pricing and innovation: what is the story? Managerial Decis Econ 2007, 28:407-413.
• [17]Møllgaard P, Overgaard PB: Transparency and Competition Policy. In The Pros and Cons of Information Sharing. Stockholm, Sweden: Swedish Competition Authority; 2006:101-129.
• [18]van Dongen S: Websites Reporting Medicine Prices: A Comparative Analysis. Geneva, Switzerland: World Health Organization in assoc. with Department of Pharmaceutical Sciences, Utrecht University, the Netherlands; 2010.
• [19]Danzon PM, Chao L: Cross-national price differences for pharmaceuticals: how large, and why? J Health Econ 2000, 19:159-195.
• [20]Kaddar M: New project to provide lower-middle and middle-income countries with up-to-date product, price and procurement information. Global Immunization News 2011. http://www.who.int/immunization/GIN_August_2011.pdf webcite (Accessed 17 April 2013)
• [21]World Health Organization: Global price reporting mechanism. http://apps.who.int/hiv/amds/price/hdd webcite. (Accessed March 15, 2013)
• [22]Health Action International: Medicine prices, availability, affordability & price components. http://www.haiweb.org/medicineprices webcite. (Accessed March 15, 2013)
• [23]Management Sciences for Health: International drug price indicator guide. http://erc.msh.org/priceguide webcite (Accessed March 15, 2013)
• [24]World Health Organization, Western Pacific Region: Price information exchange for selected medicines in the western pacific region. http://www.piemeds.com webcite (Accessed March 15, 2013)
• [25]The Global Fund: Price and quality reporting. http://www.theglobalfund.org/en/procurement/pqr webcite (Accessed March 15, 2013)
• [26]MSF Access Campaign: Untangling the web of antiretroviral price reductions. http://utw.msfaccess.org webcite. (Accessed March 15, 2013)
• [27]Médecins Sans Frontières: Untangling the Web of antiretroviral price reductions. http://d2pd3b5abq75bb.cloudfront.net/2012/11/27/10/34/06/884/MSF_Access_UTW_15th_Edition_2012_updatedOct2012.pdf webcite (Accessed April 17, 2013)
• [28]World Health Organization: Global Status Report on Noncommunicable Diseases. Geneva, Switzerland; 2010.
• [29]Waning B, Kaplan W, King AC, Lawrence DA, Leufkens HG, Fox MP: Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull World Health Org 2009, 87:520-528.